地舒单抗作用效果

It is a fully humanized neutralizing antibody that binds RANKL and was approved by the US FDA in November 2010 for the treatment of bone metastasis from solid tumors.

Cancer metastasis is the main cause of death, and bone is the third most common site of metastasis. Desosumab can prevent RANKL from binding to its receptor substances, inhibit osteoclast activation and development, reduce bone resorption, and increase bone density. Desosumab is an injection of 120 mg subcutaneously into the upper arm, upper thigh, or abdomen once every 4 weeks. Calcium and vitamin D are given when treatment or prevention of hypocalcemia is required. Let’s take a look at how denosumab works.

Three randomized-double-blind clinical studies confirmed the safety and efficacy of denosumab, with a total of 5,723 patients participating in the studies. These studies compared denosumab with zoledronic acid in patients with breast cancer, prostate cancer, and various other cancers. The studies were designed to measure the time between patients ultimately suffering a fracture or spinal cord compression due to cancer, or requiring radiation or surgery to control pain. In patients with prostate cancer, denosumab delayed SREs better than zoledronic acid. The median delay in SREs in patients with prostate cancer was 21 months and 17 months with zoledronic acid. In patients with breast cancer, zoledronic acid delayed SREs for a median of 26 months, whereas denosumab did not achieve this level. In patients with other solid tumors, denosumab and zoledronic acid delayed SREs by similar median times. The main solid tumors of the subjects were non-small cell lung cancer, multiple myeloma, renal cancer and small cell lung cancer.

Generally speaking, the effect is quite good, and the effects in the treatment of different diseases vary. On May 27, 2019, Amgen China announced that denosumab has been approved by the National Medical Products Administration for the treatment of giant cell tumors of bone that are unresectable or whose surgical resection may cause severe functional disability, including adults and adolescent patients with skeletal maturity (defined as at least 1 mature long bone and body weight >45 kg).